Phase II Study of Docetaxel and Trametinib in Patients with <i>KRAS</i> Mutation Positive Recurrent Non–Small Cell Lung Cancer (NSCLC; SWOG S1507, NCT-02642042)
Shirish M. Gadgeel(Chinese University of Hong Kong), Karen Kelly(Cancer Research Center), Wallace Akerley(University of Utah), Gregory J. Gerstner(Illinois CancerCare), Asma Taj(St. Mary's Medical Center), David R. Gandara(University of California, Davis), Timothy F. Burns(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Mary W. Redman(Fred Hutch Cancer Center), Noel Laudi(Metro-Minnesota Community Oncology Research Consortium), Konstantin H. Dragnev(Dartmouth Cancer Center), Jieling Miao(Fred Hutch Cancer Center), Jonathan W. Riess(University of California Davis Medical Center), Jhanelle E. Gray(Moffitt Cancer Center), James Moon(Fred Hutch Cancer Center), Philip C. Mack(UC Davis Comprehensive Cancer Center)
Cited by 21
Related Papers
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2008|3.2k
Alectinib versus Crizotinib in Untreated <i>ALK</i>-Positive Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2017|2.4k
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|1.4k